Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years COMMENT

被引：0
|
作者：
Chin, Joseph L. [1 ]
机构：
[1] Western Univ, Urol & Oncol, London, ON, Canada
来源：
JOURNAL OF UROLOGY | 2019年 / 202卷 / 06期
关键词：
D O I：
10.1097/01.JU.0000582668.13559.54
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1198 / 1198
页数：1
相关论文
共 50 条
  • [21] INTERMEDIATE-TERM ONCOLOGIC AND FUNCTIONAL OUTCOMES AFTER SALVAGE CRYOABLATION FOR LOCALIZED, BIOPSY-PROVEN RECURRENT PROSTATE CANCER FOLLOWING PRIMARY EXTERNAL BEAM RADIOTHERAPY VERSUS PRIMARY CRYOTHERAPY
    Campbell, Scott P.
    Arcot, Rohith
    Deivasigamani, Sriram
    Adams, Eric S.
    Orabi, Hazem
    Elshafei, Ahmed
    Tan, Wei Phin
    Davis, Leah
    Wu, Yuan
    Chang, Andrew
    Jones, J. Stephen
    Polascik, Thomas J.
    JOURNAL OF UROLOGY, 2023, 209 : E1042 - E1043
  • [22] Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline EDITORIAL COMMENT
    Gild, Philipp
    Abdollah, Firas
    JOURNAL OF UROLOGY, 2017, 198 (02): : 361 - 361
  • [23] Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes
    Sahin, Hayrettin
    Deliktas, Hasan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 113 - 119
  • [24] High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series EDITORIAL COMMENT
    Valerio, Massimo
    JOURNAL OF UROLOGY, 2020, 204 (04): : 747 - 747
  • [25] Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry
    Tay, Kae Jack
    Polascik, Thomas J.
    Elshafei, Ahmed
    Cher, Michael L.
    Given, Robert W.
    Mouraviev, Vladimir
    Ross, Ashley E.
    Jones, J. Stephen
    JOURNAL OF ENDOUROLOGY, 2016, 30 (01) : 43 - 48
  • [26] Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer
    Bryant, Alex K.
    McKay, Rana R.
    Kader, A. Karim
    Parsons, J. Kellogg
    Einck, John P.
    Kane, Christopher J.
    Mundt, Arno J.
    Murphy, James D.
    Rose, Brent S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : 1068 - 1076
  • [27] Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance
    Whalen, Michael J.
    Pak, Jamie S.
    Lascano, Danny
    Ahlborn, David
    Matulay, Justin T.
    McKiernan, James M.
    Benson, Mitchell C.
    Wenske, Sven
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E425 - E435
  • [28] Five-Year Outcomes of Proton Therapy in Localized Prostate Cancer on 3 Prospective Trials for Low-, Intermediate-, and High-Risk Prostate Cancer
    Mendenhall, N. P.
    Hoppe, B. S.
    Morris, C. G.
    Nichols, R. C.
    Mendenhall, W. M.
    Su, Z.
    Li, Z.
    Williams, C. R.
    Costa, J.
    Henderson, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S155 - S155
  • [29] Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes EDITORIAL COMMENT
    Lepor, Herbert
    JOURNAL OF UROLOGY, 2017, 198 (02): : 343 - 344
  • [30] Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer
    Bul, Meelan
    van den Bergh, Roderick C. N.
    Zhu, Xiaoye
    Rannikko, Antti
    Vasarainen, Hanna
    Bangma, Chris H.
    Schroder, Fritz H.
    Roobol, Monique J.
    BJU INTERNATIONAL, 2012, 110 (11) : 1672 - 1677
12345